Latest News

Patents and access to medicine in the US

This New York Times article shows how prescription asthma medication costs $250 a month in the US, because of longer patents and no price regulation, compared with a maximum of $36.10 for prescription medicines in Australia. This could happen here if US pharmaceutical companies succeed in using the Trans-Pacific Partnership Agreement (TPPA) to extend patents and to prevent governments from regulating medicine prices.

Lateline: Trans-Pacific Partnership could damage Australia

ABC TV program Lateline aired concerns about the Trans-Pacific Partnership Agreement (TPPA) including the potential impact on public health and medicines, as well as investor-state dispute settlement (ISDS).

The feature includes an interview with AFTINET's Convener Dr Patricia Ranald and former Trade Minister Richard Marles (now Opposition Trade Spokesperson).

Watch the program or read the transcript here

TPPA leaders’ statement hides deep divisions caused by extreme US demands

“The stated goal of the TPP Leaders’ and Ministers’ Statements to conclude the TPPA this year is unlikely to be achieved. The bland language hides deep divisions between the 12 diverse governments, caused by extreme US demands,” Dr Patricia Ranald, Convenor of the Australian Fair Trade and Investment Network said today. Dr Ranald is in Bali monitoring the TPPA talks which took place at the 21-nation APEC Leaders’ meeting.

Read the media release.

Pages